18129-Lung Cancer-NA-129

Lung Cancer

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Address

1800 Williams St, Suite 200
Denver, CO 80218
P: (303) 388-4876

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.